We are live on ! Find out more
CPHI icon

China Pharma Holdings

9 hedge funds and large institutions have $1.41M invested in China Pharma Holdings in 2013 Q4 according to their latest regulatory filings, with 3 funds opening new positions, 0 increasing their positions, 5 reducing their positions, and 0 closing their positions.

New
Increased
Maintained
Reduced
Closed

29% more funds holding

Funds holding: 79 (+2)

19% more capital invested

Capital invested by funds: $1.18M → $1.41M (+$224K)

0% less ownership

Funds ownership: 0.02%0.02% (-0%)

50% less funds holding in top 10

Funds holding in top 10: 21 (-1)

100% less repeat investments, than reductions

Existing positions increased: 0 | Existing positions reduced: 5

Holders
9
Holders Change
+2
Holders Change %
+28.57%
% of All Funds
0.26%
Holding in Top 10
1
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-50%
% of All Funds
0.03%
New
3
Increased
Reduced
5
Closed
Calls
Puts
Net Calls
Net Calls Change

CPHI Hedge Fund Activity: Q4 2013 in Review

9 of the 3,459 institutional investors tracked by Wall St. Rank reported a position in China Pharma Holdings (CPHI) for Q4 2013, worth a combined $1.41M — up 19% from $1.18M a quarter earlier.

Buyers outnumbered sellers: 3 funds opened new CPHI positions and 0 closed out — a net gain of 3 holders — while 0 added to existing stakes and 5 trimmed.

The largest buyer was Citadel Advisors, opening a new position worth an estimated $14.8K. The largest seller was First Wilshire Securities Management, cutting an estimated $20.9K.

  • 9 institutional investors held China Pharma Holdings (CPHI) as of Q4 2013, up from 7 in Q3 2013.
  • Funds reported $1.41M of China Pharma Holdings stock for Q4 2013, up 19% quarter-over-quarter.
  • 3 funds opened new China Pharma Holdings positions in Q4 2013 and 0 closed out, a net change of +3 holders.
  • The largest China Pharma Holdings buyer in Q4 2013 was Citadel Advisors, an estimated $14.8K added.
  • The largest China Pharma Holdings seller in Q4 2013 was First Wilshire Securities Management, an estimated $20.9K sold.

Based on aggregated 13F filings for Q4 2013.